On the future of therapeutic vaccination in chronic hepatitis B

Julio Cesar Aguilar Rubido*,1
1Head, Hepatitis B Therapeutic Vaccine Project, Center for Genetic Engineering & Biotechnology Ave. 31/158 & 190, Playa, Havana 10600, Cuba
*Author for correspondence: Tel.: +53 5357 4176; julio.aguilar@cigb.edu.cu

“The even after the exciting Phase I/II results, several companies have stopped studies with their candidates since they failed to fulfill specific clinical end points in subsequent trials. A closer look into these clinical results is required.”

First draft submitted: 5 September 2019; Accepted for publication: 19 September 2019; Published online: 30 October 2019

Keywords: chronic hepatitis B • clinical trials • vaccination

According to the WHO, approximately 254 million patients are chronic carriers of hepatitis B virus (HBV) and the fatalities are in the range of 0.5 to 1 million patients per year [1]. Only a small fraction of patients requiring treatment are on therapy. Untreated patients are at risk of suffering liver cirrhosis and hepatocellular carcinoma.

Chronic hepatitis B (CHB) is one of the diseases where therapeutic vaccination has been tested with enthusiasm and hope, due to the limitations and low effectiveness [2] of current treatments. Although hepatitis B commercial vaccines are efficient in preventing HBV infection, they have failed in the therapeutic setting, leading to the development of more potent vaccine candidates.

Therapeutic vaccination can be conceptualized as the immunization strategy aimed at activating or modifying the immune system in order to cure, control or limit the progression of a specific pathological condition, using an active and specific stimulation of the immune system. This therapeutic approach has been attempted in the fields of chronic infectious diseases, cancer, autoimmunity, allergy and the treatment of addiction to several drugs.

The working hypothesis of therapeutic vaccination in the field of CHB is based on the understanding of the immunological profile of patients with natural- or treatment-induced serological and virological responses, in contrast to the profile induced in those unable to control HBV replication and the related liver damage. Mimicking this immune profile, several vaccine candidates were developed and tested. Even after the exciting Phase I/II results, several companies have stopped studies with their candidates since they failed to fulfill specific clinical end points in subsequent trials. A closer look into these clinical results is required.

Actions have been taken to improve therapeutic vaccines: inclusion of new antigens; the use of different routes of administration; changes in the vaccination schedule; the inclusion of potent adjuvants; the optimization of the antigen dose, etc. One of the reasons of their failure may be the fact that most of these clinical trials were conducted in patients under a deep and long-standing viral suppression [3–5].

The rationale of therapeutic vaccination when administered under viral suppression, is based on the observation that a decrease in viral load often precedes the detection of anti-HBV-specific T-cell responses, both in patients resolving natural infections and in those achieving HBeAg seroconversion during the chronic infection. Thus, a reduction in HBV load by antiviral treatment with nucleos(t)ide analogs (NUC) may increase the responsiveness of HBV-specific T cells, which are hyporesponsive in cases of persistent HBV infection [6]. However, changes in viral load have immunological repercussion.

Increased HBV-specific T-cell responses are detectable during the first few months of lamivudine treatment [7]; however, this restoration of T-cell activity is partial, transient and does not lead to an increase in HBeAg seroconversion [8], suggesting that the timing for vaccination is a relevant variable. On the other hand, the patients restarted NUC treatment very soon after discontinuation, just after the first detection of HBV DNA, or when there was evidence of HBV replication at low levels [9–11], following a conservative approach.
There are some theoretical disadvantages related to immunizing patients under long-term antiviral treatment. Vaccine-induced T cells should exert their function in the liver. However, the anti-inflammatory liver environment is reinforced, as reflected by the reduction in alanine amino transferase (ALT) levels in most patients few weeks after the start of antiviral treatment [9–11]. In line with this, it has been demonstrated that hepatocytes do not express HLA class II, except under inflammatory conditions [12–14], a logical and natural adaptation to the tolerogenic role of the liver, further reducing the antigenicity of hepatocytes in patients without treatment.

The suppression of viral replication in patients under NUC therapy leads to a reduction in the number of hepatocytes presenting viral antigens, such as cytoplasmic HBCAg. It has been demonstrated that the control of the replication can be predicted by the low intracellular expression of HBCAg [15]. Taken together, in virally suppressed patients, there is a reduced presentation of HBV antigens and consequently a reduction in the presentation of viral peptides to vaccine-induced T cells both by HLA class I and II. Viral replication reactivates the immune system detection mechanisms, restarting the immune response. In fact, nucleos(t)ide analog (NUC) treatment discontinuation may be useful for immunotherapeutic efficacy improvement; however the design of the discontinuation and restart treatment protocol needs to be changed.

HeberNasvac, a therapeutic vaccine used as a monotherapy, was compared with pegylated interferon (PegIFN) in an efficacy Phase III clinical trial [16]. This product was shown to be safer than PegIFN and more effective in terms of HBV DNA suppression. HeberNasvac also demonstrated a better serological response and a slower progression of fibrosis, linked to a lower number of complications in the 5-year follow-up period when compared with PegIFN [17–21]. It is noteworthy that the recent, long-lasting studies comparing PegIFN with antivirals support the superiority of PegIFN for the prevention of unfavorable events (cirrhosis, hepatocellular carcinoma, death) [22], even when the suppression of HBV is less pronounced compared with the effect of antiviral treatment. In this context, HeberNasvac’s superiority compared with PegIFN deserves a closer look by WHO and other international organizations due to the safety profile of this product, having the potential of being applied to all chronic hepatitis B patients.

The sanitary registration granted to HeberNasvac in its country of origin (Cuba) as well as the first international activities with this product in Japan [23] and other countries in Asia, are encouraging news. HeberNasvac represents a finite and safe alternative for CHB treatment as a monotherapy. In addition, smart combinations with NUCs or PegIFN are also possible since it is a fully developed industrial product and, at present, administered in several hundreds of patients around the world as well as starting sanitary registration in several countries [24].

**Future opportunities in the field of therapeutic vaccination**

There is still a long road ahead in the optimization of this product. In fact, the first clinical evaluation of HeberNasvac combined with NUC failed to demonstrate the expected efficacy according to the trial design [25,26]. Therapeutic vaccination combined with some of the novel therapeutic drugs under development [26] represents a wide opportunity for future research. However, the study of smart combinations with NUC treatment may overcome the immunological limitations found in past studies.

Major associations for the study of the liver support antiviral treatment discontinuation under strict monitoring in noncirrhotic HBeAg-negative patients, with long-time virological suppression and low fibrosis. The recommendations of treatment discontinuation in HBeAg-negative patients was preceded by a strong meta-analysis that detected the increase of the anti-HBV immune response after NUC cessation, as a consequence of viral rebound. ALT increases, in patients with low levels of fibrosis and under strict assessment, are considered benign in nature and reflect an immune activation that leads to HBsAg elimination in 20–40% of the patients in the 3-year follow-up period. On the other hand, patients continuing treatment with NUCs evidenced no reduction in their serum HBsAg levels [27–30].

The European Association for the Study of the Liver (EASL) has established rules for restarting therapy based on the absence of response, or on a clear and sustained re-emergence of the ALT and HBV DNA. Transient and moderate ALT increases after viral rebound are considered physiologically normal. This is later naturally controlled by the immune system. After a solid meta-analysis [27], EASL guidelines proposed the restart of NUC treatment, several months after discontinuation and specific rules were put in place.

The currently used clinical trial methodology should be adjusted to implement the novel guidelines proposed in patients discontinuing antiviral treatment. Such modifications favor the incorporation of patients currently under NUC treatment and wishing to stop antiviral treatment after several years. A potential increase in serological
On the future of therapeutic vaccination in chronic hepatitis B

Editorial

responses is likely to occur in such conditions [27]. Hence, a new horizon of opportunities is created for therapeutic vaccination approaches.

A rational design of vaccination in the setting of NUC interruption may also contribute to find a solution for patients needing antiviral treatment cessation due to economic or medical reasons. In this group, ALT exacerbation post-treatment cessation is frequent. In fact, irregular medication with NUCs is one of the major causes of decompensation and acute on chronic liver failure [31]. Thus, the modulation in the pattern of immune response with the use of vaccination around or after treatment cessation, should modulate the immunological pattern associated with viral rebound and ALT exacerbation associated to decompensation, in favour of shorter and beneficial flares related to the Th1 immune response induced by the vaccine [32].

An approach already under study proposes the use of NUC for a longer period of time after therapeutic vaccination. This approach is intended to favor HBsAg seroconversion without losing the virological, serological and biochemical gain from NUC therapy. In the specific case of HBeAg-negative patients under NUC, HBsAg remains as the only serological variable. The accomplishment of this concept represents a new strategy; in short, more time is given to the immune system to work under virological suppression [29]. The results of this new trial should provide light on this novel approach, leading to NUC treatment discontinuation only after the consolidation of HBsAg elimination.

In summary, therapeutic vaccination has the potential to modify immune reactivation after treatment cessation. Alternatively, the use of NUC for a longer period of time after therapeutic vaccination should favor HBsAg seroconversion without losing the virological, serological and biochemical gain from NUC therapy. Then, the future of therapeutic vaccination in CHB remains alive and strong, both as a monotherapy and in the setting of rationally combined treatments.

Financial & competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Open access

This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

1. Global Hepatitis Report 2017. WHO, Geneva, Switzerland (2017).
2. Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 142(6), 1360–1368 (2012).
3. Lok AS, Pan CQ, Han SH et al. Randomized Phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis. B. J. Hepatol. 65(3), 509–516 (2016).
4. Fontaine H, Kahi S, Chazallon C et al. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial–ANRS HB02 VAC-ADN. Gut 64(1), 139–147 (2015).
5. Vandepapelière P, Lau GK, Leroux-Roels G et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 25(51), 8585–8597 (2007).
6. Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J. Hepatol. 54(6), 1286–1296 (2011).
7. Boni C, Bertolletti A, Penna A et al. Lamivudine treatment can restore T-cell responsiveness in chronic hepatitis. B. J. Clin. Invest. 102(5), 968–975 (1998).
8. Boni C, Penna A, Bertolletti A et al. Transient restoration of anti-viral T-cell responses induced by lamivudine therapy in chronic hepatitis B. J. Hepatol. 39(4), 595–605 (2003).
9. Lok AS, Pan CQ, Han SH et al. Randomized Phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J. Hepatol. 65(3), 509–516 (2016).
10. Fontaine H, Kahi S, Chazallon C et al. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial–ANRS HB02 VAC-ADN. Gut 64(1), 139–147 (2015).
11. Vandepapelière P, Lau GK, Leroux-Roels G et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 25(51), 8585–8597 (2007).

12. Knolle PA. Staying local-antigen presentation in the liver. Curr. Opin. Immunol. 40(3), 36–42 (2016).

13. Krawitt EL, Zannier A, Chossegros P et al. Expression of HLA antigens and T-cell infiltrates in chronic viral hepatitis. A comparison of biopsy and fine-needle aspiration findings. J. Hepatol. 12(2), 190–194 (1991).

14. van den Oord JJ, de Vos R, Desmet VJ. In situ distribution of major histocompatibility complex products and viral antigens in chronic hepatitis B virus infection: evidence that HBC-containing hepatocytes may express HLA-DR antigens. Hepatology 65(6), 981–989 (1986).

15. Unzu Y, Bozkaya H, Ereden E et al. Hepatitis B core antigen expression pattern reflects the response to anti-viral treatment. J. Gastroenterol. Hepatol. 21(6), 977–981 (2006).

16. NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients (NASVAC). ClinicalTrials.gov Identifier: NCT01374308 (2019). https://www.clinicaltrials.gov/ct2/show/NCT01374308?term=Nasvac&rank=1

17. Betancourt AA, Delgado CA, Estévez ZC et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int. J. Infect. Dis. 11(5), 394–401 (2007).

18. Al-Mahtab M, Akbar SM, Aguilar JC, Uddin MH, Khan MS, Rahman S. Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B. Hepatol. Int. 7(4), 981–998 (2013).

19. Al-Mahtab M, Akbar SMF, Aguilar JC et al. Treatment of chronic hepatitis B naive patients with a therapeutic vaccine containing HBs and Hbc antigens (a randomized, open and treatment controlled Phase III clinical trial). PLoS ONE 13(8), e0201236 (2018).

20. Fernández G, Sanchez AL, Jerez E et al. Five-year follow-up of chronic hepatitis B patients immunized by nasal route with the therapeutic vaccine HeberNasvac. Eurovision J. Hepatogastroenterol. 82(2), 133–139 (2018).

21. Aguilar JC, Aguilar J, Guillin G, Penton E, Fernandez G. Five years follow-up of chronic hepatitis B patients immunized by nasal route with the therapeutic vaccine HeberNasvac. J. Hepatol. 68, S516 (2018).

22. Li SY, Li H, Xiong YL et al. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBsAg-positive chronic hepatitis B: a five-year observational cohort study, J. Viral Hepat. 24, 12–20 (2017).

23. Yoshida O, Imai Y, Akbar SMF et al. A nasal adjuvantive therapeutic vaccine (NASVAC) with modified treatment strategy reduces and eliminates HBs antigen in HBV infected patients with or without nucleos(t)ide analogs therapy. AASLD Abstracts. Hepatol. 68(1), 2 (2018).

24. HeberNasvac: Recombinant therapeutic vaccine against the chronic Infection by the Hepatitis B Virus. Cuban Regulatory Agency (CECMED). Summary of product characteristics (2019). https://www.cecmd.cu/sites/default/files/adjuntos/rcp/biologicos/rcp_hebernasvac_0.pdf

25. Wedemeyer H, Hui AJ, Sukeepaisarnjaroen W et al. Therapeutic vaccination of chronic hepatitis B patients with ABX203 (NASVAC) to prevent relapse after stopping NUCs: contrasting timing rebound between tenofovir and entecavir. Int. J. Infec. Dis. 11(Suppl. 1), S97 (2017).

26. Aguilar JC, Van de Klundert M, Michel M-L. The International Liver Congress™, Amsterdam, the Netherlands 2017. Biotecnol. Aplicada 34, 2511–2521 (2017).

27. Papatheodoridis G, Vlachogiannakos I, Cholongitas E et al. Discontinuation of oral antivirals in chronic hepatitis B: a systematic review. Hepatology 63(5), 1481–1492 (2016).

28. Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative chronic hepatitis B virus infection: evidence that HBc-containing hepatocytes may express HLA-DR antigens. Hepatology 65(6), 981–989 (1986).

29. Berg T, Simon KG, Mauss S. In situ distribution of major histocompatibility complex products and viral antigens in chronic hepatitis B virus infection: evidence that HBC-containing hepatocytes may express HLA-DR antigens. Hepatology 65(6), 981–989 (1986).

30. Flink HJ, Sprenger D, Hansen BE et al., HBV 99–01 Study Group. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy. Gut 54(11), 1604–1609 (2005).